![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Background and aims: The etiology of gastric cancer is unclear; its therapeutic effect is poor; the anatomical factor and lack of specific diagnostic markers are part of the reason. Recent reports indicate corticotropin releasing hormone (CRH) is associated with the pathogenesis of cancer. This study is designed to assess the levels of CRH in gastric tissue of a group of patients with gastric cancer and gastric chronic inflammation. Methods: Fifty-two patients with gastric cancer (GC) and 213 patients with gastric chronic inflammation were recruited into this study. The levels of CRH in the gastric biopsies were assessed. The correlation between the levels of CRH in the gastric biopsies and the tumorigenesis was assessed. Results: High levels of (458.6 pg/mg protein) CRH were detected in the biopsies of 52 patients with gastric cancer, which were also detected in the gastric biopsies of 213 patients with chronic gastritis (less than 100 pg/mg protein). CRH was below the detectable levels in the normal gastric mucosa. Of the 213 patients with chronic gastritis, 50 patients developed into cancer 3–5 years after the first diagnosis of chronic gastric cancer. Conclusions: CRH may be involved in the pathogenesis of gastric cancer.